Considerations To Know About QST4
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To guage multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary trial goals were To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis suffer